Why Sanofi’s Tzield expansion changes the treatment window for type 1 diabetes
Discover how Sanofi’s Tzield approval could reshape newly diagnosed pediatric type 1 diabetes care and why major clinical questions remain.
Pharma & Biotech
Pharma & Biotech
Sanofi’s Tzield gains pediatric approval but can early intervention truly change T1D outcomes
FDA expands Tzield use to young children with type 1 diabetes. Discover what this means for early intervention and long-term outcomes.